Improved perception of IGLARLIXI therapy compared to mixed insulin when transferred from basal insulin: outcomes reported by patients in the SoliMix study
https://doi.org/10.15829/2713-0177-2023-3-13
Abstract
Since type 2 diabetes mellitus (DM2) is characterized by a progressive loss of pancreatic beta cell function, there is a need to add insulin to current therapy in order to compensate for the disease and prevent the development of complications. The clinical recommendations suggest various options for the intensification of DM2 therapy: both monopreparations of insulin and its combination with aGPP-1. The latter have demonstrated clinical efficacy in achieving glycemic control and a favorable safety profile in clinical trials. Another important issue is the perception of treatment by the patient himself, since for many people, changing therapy or changing the “format” itself (prescribing injections) can be accompanied by additional stress.
The purpose of this study was to study the efficacy and safety, as well as the perception of patients with treatment of DM2 when using a fixed combination of insulin glargine/lixisenatide (Iglarlixi) compared with mixed insulin – biphasic aspartame 30.
About the Authors
E. A. Yanovskaya
Federal State Budgetary Educational Institution of Higher Education Yaroslavl State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
Assistant at the Department of Therapy named after Professor E. N. Dormidontov
Yaroslavl
M. E. Yanovskaya
Federal State Budgetary Educational Institution of Higher Education Yaroslavl State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
Candidate of Medical Sciences, Head of the Endocrinology Department
Yaroslavl
References
1. Демидова Т. Ю., Титова В. В. Инсулинотерапия – персонализированный подход к управлению гликемией при сахарном диабете // Терапевтический архив. – 2020. – Т. 92. – № 12. – C. 201–206. doi: 10.26442/00403660.2020.12.200449.
2. Abu Hassan H, Tohid H, Mohd Amin R, Long Bidin MB, Muthupalaniappen L, Omar K. Factors influencing insulin acceptance among type 2 diabetes mellitus patients in a primary care clinic: a qualitative exploration. BMC Fam Pract. 2013 Oct 29;14:164. doi: 10.1186/1471-2296-14-164. PMID: 24164794; PMCID: PMC4231611.
3. Rosenstock J, Emral R, Sauque- Reyna L, et al.SoliMix Trial Investigators. Advancing Therapy in Suboptimally Controlled Basal Insulin- Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial. Diabetes Care. 2021 Jun 28;44(10):2361–70. doi: 10.2337/dc21-0393. Epub ahead of print. PMID: 34183429; PMCID: PMC8740944.
4. Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299–307.
5. Polonsky, W., et al. “Improved Treatment Perceptions with iGlarLixi vs Premix Insulin in Type 2 Diabetes (T2D) Uncontrolled on Basal Insulin (BI) + Oral Antihyperglycemic Drugs (OADs): Patient- reported Outcomes (PROs) of the SoliMix Trial”, Presentation 747-P, American Diabetes Association (ADA) 81st Scientific Sessions (virtual event), June 28, 2021.
Review
For citations:
Yanovskaya E.A., Yanovskaya M.E. Improved perception of IGLARLIXI therapy compared to mixed insulin when transferred from basal insulin: outcomes reported by patients in the SoliMix study. FOCUS. Endocrinology. 2023;4(3):36-40. (In Russ.) https://doi.org/10.15829/2713-0177-2023-3-13
Views:
204
Email this article 